The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 30, 2020
Filed:
Aug. 09, 2017
Applicant:
Takeda Pharmaceutical Company Limited, Osaka, JP;
Inventors:
Jun Fujimoto, Kanagawa, JP;
Xin Liu, Shanghai, CN;
Osamu Kurasawa, Kanagawa, JP;
Terufumi Takagi, Kanagawa, JP;
Douglas Robert Cary, Tokyo, JP;
Hiroshi Banno, Kanagawa, JP;
Yasutomi Asano, Kanagawa, JP;
Takuto Kojima, Kanagawa, JP;
Assignee:
TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 401/14 (2006.01); C07D 213/75 (2006.01); C07D 405/12 (2006.01); C07D 239/42 (2006.01); C07D 241/12 (2006.01); C07D 471/04 (2006.01); C07D 498/04 (2006.01); C07D 213/65 (2006.01); A61P 35/00 (2006.01); C07D 241/20 (2006.01); C07D 213/73 (2006.01); A61K 31/53 (2006.01); A61K 31/505 (2006.01); A61K 31/4406 (2006.01); A61K 31/444 (2006.01); A61K 31/4965 (2006.01); C07D 213/68 (2006.01); C07D 213/42 (2006.01); A61K 31/506 (2006.01); A61K 31/497 (2006.01); A61K 31/4375 (2006.01); C07D 239/20 (2006.01); A61P 43/00 (2006.01); A61K 31/5383 (2006.01); A61K 31/437 (2006.01); A61K 31/44 (2006.01); C07D 253/06 (2006.01); C07D 231/12 (2006.01); C07D 239/30 (2006.01); C07D 239/34 (2006.01); C07D 239/48 (2006.01); C07D 253/07 (2006.01); C07D 409/12 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 401/12 (2013.01); A61K 31/437 (2013.01); A61K 31/4375 (2013.01); A61K 31/44 (2013.01); A61K 31/444 (2013.01); A61K 31/4406 (2013.01); A61K 31/497 (2013.01); A61K 31/4965 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/53 (2013.01); A61K 31/5383 (2013.01); A61P 35/00 (2018.01); A61P 43/00 (2018.01); C07D 213/42 (2013.01); C07D 213/65 (2013.01); C07D 213/68 (2013.01); C07D 213/73 (2013.01); C07D 213/75 (2013.01); C07D 239/20 (2013.01); C07D 239/42 (2013.01); C07D 241/12 (2013.01); C07D 241/20 (2013.01); C07D 253/06 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 471/04 (2013.01); C07D 498/04 (2013.01); C07D 231/12 (2013.01); C07D 239/30 (2013.01); C07D 239/34 (2013.01); C07D 239/48 (2013.01); C07D 253/07 (2013.01); C07D 409/12 (2013.01); C07D 487/04 (2013.01);
Abstract
Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.